{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:17:40Z","timestamp":1791289060182,"version":"4.3.0"},"reference-count":44,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[2002,7,15]]},"abstract":"<jats:p> PURPOSE: The objectives of this phase II study were to determine survival, safety, pharmacokinetics (PK), and pharmacodynamics (PD) of 2,4-[[(3,5-dimethylanilino)carbonyl]methyl]phenoxy]-2-methylpropionic acid (RSR13, efaproxiral) 100 mg\/kg per day administered with standard cranial radiotherapy (RT) for the treatment of glioblastoma multiforme (GBM). RSR13, a synthetic allosteric modifier of hemoglobin, is a radiation-enhancing agent that noncovalently binds to hemoglobin, reduces oxygen-binding affinity, and increases oxygen unloading to hypoxic tissue. <\/jats:p><jats:p> PATIENTS AND METHODS: Fifty patients with newly diagnosed GBM (Karnofsky performance status \u2265 60) were enrolled onto this multicenter phase II study. Patients received daily RSR13 100 mg\/kg intravenously infused for 30 minutes immediately before cranial RT (60 Gy in 30 fractions). Supplemental oxygen was given during RSR13 infusion and continued until after the RT treatment was completed. RT was given within 30 minutes of the end of RSR13 infusion. PK and PD determinations were performed. <\/jats:p><jats:p> RESULTS: The median survival for the RSR13-treated patients was 12.3 months with 1-year and 18-month survival rates of 54% and 24%, respectively. Twenty-four percent of patients had greater than grade 2 toxicity, which was generally transient and self-limited. A significant PD effect on hemoglobin-oxygen binding affinity was demonstrated for most patients. <\/jats:p><jats:p> CONCLUSION: RSR13 (100 mg\/kg) administered immediately before cranial RT is well tolerated and is pharmacodynamically active. Median survival in excess of 1 year is favorable. <\/jats:p>","DOI":"10.1200\/jco.2002.01.096","type":"journal-article","created":{"date-parts":[[2002,10,11]],"date-time":"2002-10-11T20:11:44Z","timestamp":1034367104000},"page":"3149-3155","source":"Crossref","is-referenced-by-count":64,"title":["Survival of Patients With Newly Diagnosed Glioblastoma Multiforme Treated With RSR13 and Radiotherapy: Results of a Phase II New Approaches to Brain Tumor Therapy CNS Consortium Safety and Efficacy Study"],"prefix":"10.1200","volume":"20","author":[{"given":"L.","family":"Kleinberg","sequence":"first","affiliation":[{"name":"From the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wake Forest University School of Medicine, Winston-Salem, NC; University of Alabama at Birmingham, AL; H. Lee Moffitt Cancer Center, Tampa, FL; University of Pennsylvania, Philadelphia, PA; University of Texas Health Science Center, San Antonio, TX; Allos Therapeutics, Inc, Denver, CO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.A.","family":"Grossman","sequence":"additional","affiliation":[{"name":"From the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wake Forest University School of Medicine, Winston-Salem, NC; University of Alabama at Birmingham, AL; H. Lee Moffitt Cancer Center, Tampa, FL; University of Pennsylvania, Philadelphia, PA; University of Texas Health Science Center, San Antonio, TX; Allos Therapeutics, Inc, Denver, CO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Carson","sequence":"additional","affiliation":[{"name":"From the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wake Forest University School of Medicine, Winston-Salem, NC; University of Alabama at Birmingham, AL; H. Lee Moffitt Cancer Center, Tampa, FL; University of Pennsylvania, Philadelphia, PA; University of Texas Health Science Center, San Antonio, TX; Allos Therapeutics, Inc, Denver, CO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Lesser","sequence":"additional","affiliation":[{"name":"From the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wake Forest University School of Medicine, Winston-Salem, NC; University of Alabama at Birmingham, AL; H. Lee Moffitt Cancer Center, Tampa, FL; University of Pennsylvania, Philadelphia, PA; University of Texas Health Science Center, San Antonio, TX; Allos Therapeutics, Inc, Denver, CO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"O\u2019Neill","sequence":"additional","affiliation":[{"name":"From the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wake Forest University School of Medicine, Winston-Salem, NC; University of Alabama at Birmingham, AL; H. Lee Moffitt Cancer Center, Tampa, FL; University of Pennsylvania, Philadelphia, PA; University of Texas Health Science Center, San Antonio, TX; Allos Therapeutics, Inc, Denver, CO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Pearlman","sequence":"additional","affiliation":[{"name":"From the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wake Forest University School of Medicine, Winston-Salem, NC; University of Alabama at Birmingham, AL; H. Lee Moffitt Cancer Center, Tampa, FL; University of Pennsylvania, Philadelphia, PA; University of Texas Health Science Center, San Antonio, TX; Allos Therapeutics, Inc, Denver, CO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Phillips","sequence":"additional","affiliation":[{"name":"From the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wake Forest University School of Medicine, Winston-Salem, NC; University of Alabama at Birmingham, AL; H. Lee Moffitt Cancer Center, Tampa, FL; University of Pennsylvania, Philadelphia, PA; University of Texas Health Science Center, San Antonio, TX; Allos Therapeutics, Inc, Denver, CO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Herman","sequence":"additional","affiliation":[{"name":"From the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wake Forest University School of Medicine, Winston-Salem, NC; University of Alabama at Birmingham, AL; H. Lee Moffitt Cancer Center, Tampa, FL; University of Pennsylvania, Philadelphia, PA; University of Texas Health Science Center, San Antonio, TX; Allos Therapeutics, Inc, Denver, CO."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gerber","sequence":"additional","affiliation":[{"name":"From the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Wake Forest University School of Medicine, Winston-Salem, NC; University of Alabama at Birmingham, AL; H. Lee Moffitt Cancer Center, Tampa, FL; University of Pennsylvania, Philadelphia, PA; University of Texas Health Science Center, San Antonio, TX; Allos Therapeutics, Inc, Denver, CO."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"R1-111243","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2299(199605)38:1<1::AID-DDR1>3.0.CO;2-O"},{"key":"R2-111243","doi-asserted-by":"crossref","unstructured":"Khandelwal  SR,   Kavanagh  BD,   Lin  PS,  et al:   RSR13, an allosteric effector of haemoglobin, and carbogen radiosensitize FSaII and SCCVII tumors in C3H mice.  Br J Cancer 79:  814,1998-820,","DOI":"10.1038\/sj.bjc.6690130"},{"key":"R3-111243","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050780"},{"key":"R4-111243","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6823(1996)4:2<51::AID-ROI1>3.0.CO;2-K"},{"key":"R5-111243","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)90432-4"},{"key":"R6-111243","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(94)00494-6"},{"key":"R7-111243","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(89)90936-X"},{"key":"R8-111243","unstructured":"Teicher  BA,   Dupuis  NP,   Emi  Y,  et al:   Increased efficacy of chemo-and radiotherapy by a hemoglobin solution in the 9L gliosarcoma.  In Vivo 9:  11,1995-18,"},{"key":"R9-111243","doi-asserted-by":"publisher","DOI":"10.1177\/107327489800500201"},{"key":"R10-111243","unstructured":"Grossman  SA,   Fisher  J,   Piantadosi  S:   The NABTT glioblastoma database:  An objective means to select novel agents for phase III testing.   Proc Am Soc Clin Oncol 17:  406a,1998  (abstr 1565)"},{"key":"R11-111243","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2593"},{"key":"R12-111243","doi-asserted-by":"publisher","DOI":"10.1021\/jm00106a041"},{"key":"R13-111243","doi-asserted-by":"publisher","DOI":"10.1021\/bi00153a005"},{"key":"R14-111243","doi-asserted-by":"crossref","unstructured":"Khandelwal  SR,   Randad  RS,   Lin  P-S,  et al:   Enhanced oxygenation in vivo by allosteric inhibitors of hemoglobin saturation.  Am J Physiol 34:  H1450,1993-H1453,","DOI":"10.1152\/ajpheart.1993.265.4.H1450"},{"key":"R16-111243","doi-asserted-by":"publisher","DOI":"10.3109\/10731199509117958"},{"key":"R18-111243","unstructured":"Kim  CY,   Tsai  MH,   Osmanian  C,  et al:   Selection of human cervical epithelial cells that posses reduced apoptotic potential to low-oxygen conditions.  Cancer Res 57:  4200,1997-4204,"},{"key":"R19-111243","doi-asserted-by":"publisher","DOI":"10.1038\/379088a0"},{"key":"R20-111243","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-4296(96)80035-X"},{"key":"R21-111243","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2184.1993.tb00003.x"},{"key":"R22-111243","unstructured":"Krtolica  A,   Ludlow  JW:   Hypoxia arrests ovarian carcinoma cell cycle progression, but invasion is unaffected.  Cancer Res 56:  1168,1996-1173,"},{"key":"R23-111243","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(97)00090-X"},{"key":"R24-111243","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(97)01929-4"},{"key":"R25-111243","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-4296(96)80036-1"},{"key":"R26-111243","doi-asserted-by":"publisher","DOI":"10.2307\/3573702"},{"key":"R27-111243","doi-asserted-by":"publisher","DOI":"10.2307\/3570400"},{"key":"R28-111243","doi-asserted-by":"publisher","DOI":"10.2307\/3570768"},{"key":"R29-111243","doi-asserted-by":"publisher","DOI":"10.2307\/3577618"},{"key":"R30-111243","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-4296(96)80032-4"},{"key":"R31-111243","doi-asserted-by":"publisher","DOI":"10.2307\/3570739"},{"key":"R32-111243","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(88)90002-8"},{"key":"R33-111243","unstructured":"Vaupel  P,   Schlenger  K,   Knoop  C,  et al:   Oxygenation of human tumors:  Evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements.   Cancer Res 51:  3316,1991-3322,"},{"key":"R34-111243","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-4296(96)80031-2"},{"key":"R35-111243","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(97)00101-6"},{"key":"R36-111243","unstructured":"Hockel  M,   Schlenger  K,   Knoop  C,  et al:   Oxygenation of carcinomas of the uterine cervix:  Evaluation by computerized 02 tension measurements.   Cancer Res 51:  6098,1991-6102,"},{"key":"R37-111243","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1993.1262"},{"key":"R38-111243","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(88)90002-8"},{"key":"R39-111243","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(99)00115-7"},{"key":"R40-111243","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(96)91811-3"},{"key":"R41-111243","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-8140(98)00044-9"},{"key":"R42-111243","unstructured":"Lesser  GJ,   Shaw  EG,   Lovelace  LK,  et al:   Improved intratumoral oxygenation following RSR13 infusion in man:  A case report.   Proc Am Soc Clin Oncol 17:  1596,1998  (abstr 1569)"},{"key":"R43-111243","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(01)01597-8"},{"key":"R44-111243","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(00)01412-7"},{"key":"R45-111243","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.6.1254"},{"key":"R46-111243","unstructured":"Grossman  SA,   O\u2019Neill  A,   Grunnet  M,  et al:   Phase III study comparing three cycles of infusional BCNU\/cisplatin followed by radiation and concurrent BCNU for patients with newly diagnosed supratentorial glioblastoma multiforme (ECOG 2934-SWOG 9508).  Proc Am Soc Clin Oncol 19:  612,2000  (abstr 612)"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.2002.01.096","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T09:51:06Z","timestamp":1653817866000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2002.01.096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,7,15]]},"references-count":44,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2002,7,15]]}},"alternative-id":["10.1200\/JCO.2002.01.096"],"URL":"https:\/\/doi.org\/10.1200\/jco.2002.01.096","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,7,15]]}}}